Skip to main content

Research Repository

Advanced Search

CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer (2021)
Journal Article
Uzor, S., Oltean, S., Ladomery, M., Alqasem, A., Perks, C., Wilson, I. D., …Iida, K. (2021). CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer. Scientific Reports, 11(1), https://doi.org/10.1038/s41598-021-86908-6

Dysregulation of alternative splicing is a feature of cancer, both in aetiology and progression. It occurs because of mutations in splice sites or sites that regulate splicing, or because of the altered expression and activity of splice factors and o... Read More about CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer.

Targeting the splice factor kinase CLK1 in prostate cancer cells (2020)
Thesis
Uzor, S. O. Targeting the splice factor kinase CLK1 in prostate cancer cells. (Thesis). University of the West of England. Retrieved from https://uwe-repository.worktribe.com/output/1490733

Prostate cancer is the most rampant diagnosed cancer and the second leading cause of cancer related death in men between middle age and old age. There is a need to identify the molecular genetic processes that underpin prostate cancer and to search f... Read More about Targeting the splice factor kinase CLK1 in prostate cancer cells.